Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung

Bart P.H. Wittgen, Peter W.A. Kunst, Kasper Van Der Born, Atie W. Van Wijk, Walter Perkins, Frank G. Pilkiewicz, Roman Perez-Soler, Susan Nicholson, Godefridus J. Peters, Pieter E. Postmus

Research output: Contribution to journalArticle

108 Scopus citations

Abstract

Purpose: To investigate the safety and pharmacokinetics of aerosolized Sustained Release Lipid Inhalation Targeting (SLIT) Cisplatin in patients with lung carcinoma. Experimental Design: Phase I, dose-escalating study of SLIT Cisplatin given in two sessions daily. Safety data, including laboratory variables, adverse events, pulmonary function tests, and radiographic imaging, were collected and analyzed for all patients to determine toxicity. Pharmacokinetic monitoring was done during the first course. Results: Seventeen patients and one tracheostomy patient on compassionate use received treatment. Aerosolized cisplatin was well tolerated. No dose-limiting toxicity was observed at the maximum delivered dose. Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or neurotoxicity. Most common adverse events were nausea (64.7%), vomiting (47.1%), dyspnea (64.7%), fatigue (64.7%), and hoarseness (47.1%). Pharmacokinetic data showed very low plasma platinum levels only with the longest repeated inhalations. Common Toxicity Criteria grade 2 decrease in forced expiratory volume in one second and diffusing lung capacity for carbon monoxide after one course occurred both in two patients and grade one decrease in forced expiratory volume in one second and diffusing lung capacity for carbon monoxide in six and five patients, respectively. Direct airway deposition via the tracheostomy resulted in clinical deterioration after two cycles best described as bronchitis, completely reversible within days. Overall response: stable disease in 12 patients and progressive disease in 4 patients (one patient received one cycle). Conclusions: Aerosolized liposomal cisplatin was found to be feasible and safe.

Original languageEnglish (US)
Pages (from-to)2414-2421
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number8
DOIs
StatePublished - Apr 15 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung'. Together they form a unique fingerprint.

  • Cite this

    Wittgen, B. P. H., Kunst, P. W. A., Van Der Born, K., Van Wijk, A. W., Perkins, W., Pilkiewicz, F. G., Perez-Soler, R., Nicholson, S., Peters, G. J., & Postmus, P. E. (2007). Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clinical Cancer Research, 13(8), 2414-2421. https://doi.org/10.1158/1078-0432.CCR-06-1480